Biotech Business - January 18, 2023
AlzeCure selects candidate drug and enters next phase with Alzstatin
AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company’s preventive and disease-modifying candidate drug Alzstatin ACD680. ACD680 is being developed within AlzeCure’s Alzstatin platform, with the aim of developing a preventive and disease-modifying drug for the early treatment of Alzheimer’s disease. In the project, a CD has […]
Agreement - January 17, 2023
Bristol Myers Squibb and Karolinska University Hospital enter collaboration
Karolinska University Hospital’s cancer department has signed an agreement with Bristol Myers Squibb to start an oncology and hematology research collaboration focusing on advancing research and generating data with an aim to deliver innovative therapies for patients. The organizations will centralize the work through a steering committee consisting of experts from both organizations to discuss […]
Pharma Business - January 17, 2023
IRLAB nominates Parkinson’s disease drug candidate
IRLAB Therapeutics has announced that a drug candidate has been nominated from the P003 research project. The drug candidate, IRL1117, will be developed as a once-daily oral treatment for the hallmark symptoms of Parkinson’s without inducing the troublesome complications caused by today’s mainstay anti-Parkinson’s levodopa treatments, states the company. Initiation of development towards clinical studies […]
Pharma Business - January 16, 2023
AstraZeneca’s Airsupra approved in the US for asthma
Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. “With patients experiencing more than 10 million asthma exacerbations each year in the US and uncontrolled asthma expected to cost […]
Acquisition - January 9, 2023
AstraZeneca to acquire CinCor Pharma
AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering […]
Biotech Business - January 8, 2023
FDA approves LEQEMBI under the Accelerated Approval pathway
BioArctic’s partner Eisai has announced that under the Accelerated Approval pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) for the treatment of Alzheimer’s disease. The approval concerns lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) […]
